PNC Financial Services Group
LRMR icon

PNC Financial Services Group’s Larimar Therapeutics LRMR Stock Holding History

PNC Financial Services Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43 Sell
14
-3
-18% -$12 ﹤0.01% 5176
2026
Q1 		$77 Hold
17
– – ﹤0.01% 5107
2025
Q4 		$65 Hold
17
– – ﹤0.01% 5088
2025
Q3 		$55 Hold
17
– – ﹤0.01% 5034
2025
Q2 		$49 Buy
+17
New +$39 ﹤0.01% 4865

Other funds holding LRMR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
NLP
Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return

PNC Financial Services Group's LRMR Position: Q2 2026 in Review

PNC Financial Services Group reduced its Larimar Therapeutics (LRMR) stake by 18% in Q2 2026, selling an estimated $12 and leaving 14 shares worth $43. The position accounts for ﹤0.01% of the portfolio, ranked #5176.

PNC Financial Services Group first reported a position in LRMR in Q2 2025 and has held it in 5 quarters since. The position peaked at $77 in Q1 2026. 46 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • PNC Financial Services Group held 14 shares of Larimar Therapeutics worth $43 as of Q2 2026.
  • PNC Financial Services Group sold 3 Larimar Therapeutics shares in Q2 2026, an estimated $12.
  • Larimar Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5176 holding.
  • PNC Financial Services Group first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • PNC Financial Services Group's Larimar Therapeutics position peaked at $77 in Q1 2026.
  • 46 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.